跳至主要内容
临床试验/ITMCTR1900002689
ITMCTR1900002689尚未招募1 期

Muticenter, ranfdomized and controllrd clinicl study for Haoqin Huaban Prescription in the treatment of polymorphous light eruption

Beijing Hospital of Traditional Chinese Medcine of Captial Medical University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • 1. It conforms to the diagnostic standard of polymorphous light eruption in western medicine.
  • 2. It conforms to the diagnostic standard of solar dermatitis in traditional chinese medcine.
  • 3. Aged between 18 to 65 years;
  • 4. Severity of illness:5cm2<the rash area<50cm2.

排除标准

  • 1. Other inflammatory skin diseases at exposed sites:hair dye dermatitis,contact dermatitis,etc.
  • 2. Suffer from the systemic disease such as lupus erythematosus and dermatomyositis,which increase photosensitivity.
  • 3. Combine the serious primary disorders like heart and cerebral vessels disease,liver and kindey disease,internal secretion disease, hemtopoiesis systematic disease,etc.Or mental disease will influence the experiment.
  • 4. Pregnancy or nursing woman.
  • 5. Patient who suspicious or known allergy to the ingredient of the experiment herbs.
  • 6. Other systemic disease accompanied with dyspnea,chest distress,palpitation,anhelation,nausea,emesis and swirl,ect.
  • 7. In process of other clincial medicine experiment.
  • 8. Trier who is inappropriate this reaserch.

研究者

发起方
Beijing Hospital of Traditional Chinese Medcine of Captial Medical University

相似试验

招募中
1 期
RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).Bacilliferous pulmonary tuberculosis
CTIS2023-509075-17-00Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron120
进行中(未招募)
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855
EUCTR2017-004078-32-DKSavara ApS90
进行中(未招募)
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0 Level: LLT Classification code 10037316 Term: Pulmonary alveolar proteinosis System Organ Class: 100000004855
EUCTR2017-004078-32-GBSavara ApS90
进行中(未招募)
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855
EUCTR2017-004078-32-ITSavara ApS90
进行中(未招募)
1 期
Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalatioAutoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 20.0Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855
EUCTR2017-004078-32-FRSavara ApS90